Behavioral neuroscience
October 1, 1986
L L Kwong, E R Smith, J M Davidson et al.
38 citations
Three prosexual drugs—8-OH-DPAT, 5-methoxy-dimethyltryptamine, and RDS-127—showed strong potential as selective inhibitors of 5-HT1A receptor binding, suggesting they may enhance seminal emissions and ejaculations. In contrast, yohimbine, imiloxan, and idazoxan primarily affected alpha 2-adrenergic receptors. The study analyzed interactions using radioligand binding techniques on rat brain membranes, providing insights into the mechanisms underlying sexual behavior. Understanding these interactions could pave the way for new treatments addressing sexual dysfunction.
Behavioral neuroscience
October 1, 2010
David Quinteros-Muñoz, Patricio Sáez-briones, Gabriela Díaz-véliz et al.
12 citations
MDMA (ecstasy) produces a unique set of behavioral effects in rats that distinguishes it from both stimulants and hallucinogens. In a series of behavioral tests, the effects of MDMA at various doses were compared with those of methamphetamine (a stimulant) and DOI (a hallucinogen). The behavioral profiles allowed researchers to differentiate MDMA from these other drugs. Additionally, four structural analogues of MDMA were tested, but none exactly replicated MDMA's profile, some resembling the stimulant or hallucinogen instead. This highlights MDMA's distinct pharmacological identity as an entactogen.
Behavioral neuroscience
June 1, 2024
Esther Mondragón
3 citations
A computational model of associative learning, the double error dynamic asymptote model, can help explain how spurious associations arise in schizophrenia. The model simulates mediated conditioning, mediated extinction, and a novel prediction of mediated enhancement of latent inhibition. Manipulating a parameter that controls memory retrieval and the decay of nonperceptual representations produces effects similar to those caused by ketamine on associative memories and mediated learning. The model offers a plausible error-correction mechanism that may account for associative deficits observed in animal models of schizophrenia.
Behavioral neuroscience
October 1, 2024
Dong-Hyun Youn, Cheolmin Jo, Jin Mook Kim et al.
1 citation
A new chemical, t-BOC-3,4-MDMA, is a modified form of MDMA that can evade detection in the illicit drug market and can be converted into the controlled substance MDMA. In mice, a 5 mg/kg dose of t-BOC-3,4-MDMA significantly altered place preference, indicating rewarding effects, and at 0.5 mg/kg/infusion it induced drug-taking behavior in self-administration tests. Microdialysis in rats showed that the chemical increased dopamine levels in the striatum. These findings suggest that t-BOC-3,4-MDMA has potential for misuse.